It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Regulatory T cells (Tregs) are key immune regulators that have shown promise in enhancing cardiac repair post-MI, although the mechanisms remain elusive. Here, we show that rapidly increasing Treg number in the circulation post-MI via systemic administration of exogenous Tregs improves cardiac function in male mice, by limiting cardiomyocyte death and reducing fibrosis. Mechanistically, exogenous Tregs quickly home to the infarcted heart and adopt an injury-specific transcriptome that mediates repair by modulating monocytes/macrophages. Specially, Tregs lead to a reduction in pro-inflammatory Ly6CHi CCR2+ monocytes/macrophages accompanied by a rapid shift of macrophages towards a pro-repair phenotype. Additionally, exogenous Treg-derived factors, including nidogen-1 and IL-10, along with a decrease in cardiac CD8+ T cell number, mediate the reduction of the pro-inflammatory monocyte/macrophage subset in the heart. Supporting the pivotal role of IL-10, exogenous Tregs knocked out for IL-10 lose their pro-repair capabilities. Together, this study highlights the beneficial use of a Treg-based therapeutic approach for cardiac repair with important mechanistic insights that could facilitate the development of novel immunotherapies for MI.
After myocardial infarction, excessive inflammation impairs heart repair, leading to reduced cardiac function. Here, the authors show that treatment with anti-inflammatory immune cells (regulatory T cells) improves cardiac repair by modulating the activity of a specific subset of macrophages in the heart.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Monash University, European Molecular Biology Laboratory Australia, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 Monash University, Monash Biomedical Imaging, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
3 The Walter and Eliza Hall Institute of Medical Research, Advanced Genomics Facility, Advanced Technology and Biology Division, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
4 Monash University, European Molecular Biology Laboratory Australia, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Victorian Heart Hospital, Victorian Heart Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
5 Olivia Newton-John Cancer Research Institute, Heidelberg, Australia (GRID:grid.482637.c); La Trobe University, Bundoora, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938); University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)